Is Stoke Therapeutics Inc (STOK) overvalued? · rev $36.6M
Stoke Therapeutics Inc (STOK) is a biotechnology company listed on NASDAQ.
This page asks whether Stoke Therapeutics Inc (STOK) looks expensive on cached numbers — not a short thesis.
Latest reported STOK revenue for 2024-12-31 was $36.6M. Net income was -$89.0M. Revenue was up 316.3% from 2023-12-31 to 2024-12-31. STOK currently screens at market cap $1.88B.
STOK currently screens at market cap $1.88B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next STOK 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the STOK stock page for the full model, not this heading.
Not investment advice.